Treatment of juvenile myasthenia gravis with tacrolimus: A cohort study

Abstract Background We investigated the proper timing, efficacy and safety of tacrolimus for juvenile myasthenia gravis (JMG). Methods We conducted a retrospective cohort study for JMG patients treated with tacrolimus at Xiangya Hospital, Central South University, Changsha, China from 2010 to 2023. The clinical information of patients with a follow‐up of more than 1 year was collected. Comparisons of clinical features between groups of patients who achieved therapeutic goal and those who did not achieve therapeutic goal as well as between groups of patients treated with tacrolimus within or after 1 year from JMG onset was carried out. Results Forty‐three patients were enrolled, of whom 28 achieved therapeutic goal. Tacrolimus reduced glucocorticoids (GC) dosages for the 28 cases and 15 cases discontinued GC completely. Generalized myasthenia gravis (GMG) subtype had an association with a group of patients who achieved therapeutic goal ( p = 0.001). Median duration from JMG onset to tacrolimus use was 10.50 months for those who achieved therapeutic goal and 36.00 months for those who did not achieve therapeutic goal ( p = 0.010). The median Myasthenia Gravis Activities of Daily Living (MG‐ADL) score improved significantly ( p = 0.003). The initiation of tacrolimus within 1 year of JMG onset showed an association with achievement of therapeutic goal ( p = 0.026). GMG subtype showed an association with a group of patients who received tacrolimus within 1 year ( p = <0.001). Tacrolimus side effects were tolerable. Conclusion The provision of tacrolimus within 1 year of JMG onset is effective and safe.